Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule medicines using targeted protein degradation technology. The company focuses on addressing previously undrugged disease-causing proteins, with a primary emphasis on immunology and Type 2 inflammation. Its pipeline includes KT-621, a STAT6 degrader in Phase 2b trials for atopic dermatitis and asthma, and KT-579, an oral IRF5 degrader in Phase 1 trials. Kymera collaborates with Sanofi on the IRAK4 degrader KT-485/SAR447971 and with Gilead Sciences on novel oral molecular glue degraders for CDK2. The company utilizes proprietary drug discovery capabilities, including machine learning, high-content screening, and quantitative proteomics, to identify and optimize drug candidates. Kymera operates as a fully integrated biopharmaceutical company, advancing its pipeline and expanding into other therapeutic areas where its technology platform is applicable.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage kymeratx.com
Sector Healthcare IR page investors.kymeratx.com
Tags
targeted protein degradation, immunology, small molecule medicines, molecular glue degraders, stat6, irf5, irak4, cdk2, atopic dermatitis, asthma, inflammation, KT-621, KT-579, KT-485, SAR447971, BROADEN2, BREADTH
Press page —

Metrics

Valuation  
Market cap $ 9.714B
Market cap (USD) $ 9.714B
P/E -31.36
PEG —
P/BV 6.02
P/S 247.73
P/OCF -33.78
P/FCF -33.62
Dividend yield —
Turnover / mcap —
Returns  
ROE -25.8%
ROI -25.4%
ROIC -21.4%
Profit margin -794.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 50
Quality score -82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 39.211M 47.072M 78.592M 46.826M 72.832M 34.034M 2.934M
Net profit -311.351M -223.858M -146.962M -154.808M -100.217M -45.593M -41.246M
Free cash flow -234.34M -207.339M -137.306M -155.921M -130.543M 79.034M 17.373M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 77.81 40.23 25.46 24.96 63.49 62 —
Price performance 12m 0.93 0.58 0.02 -0.61 0.02 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 0.00 15M 0.00 0.00
↳ YoY growth -100.0%
Lease liabilities (USD) 21.2M 18M 18M 17.3M 84.7M 87.8M 82.3M
Cash and deposits (USD) 76M 31M 48M 68.4M 110M 120M 357M
Right-of-use assets (USD) 18.3M 9.85M 9.43M 8.91M 52.9M 47.4M 42.4M
Cash flow detail
Operating cash flow (USD) 17.9M 88.1M -129M -153M -103M -195M -233M
Purchases of property, plant and equipment (USD) -532,000 -9.1M -1.6M -2.84M -34.5M -12.8M -1.45M
Change in payables (cash effect) (USD) 904,000 990,000 54,000 253,000 2.04M -307,000 -1.97M
Interest paid (cash effect) (USD) -46,000 -115,000 -158,000 -179,000 -162,000 -206,000 -312,000
Share-based compensation (USD) 1.2M 5.19M 25M 35.5M 43.1M 55M 59.9M
Free cash flow (OCF - PPE - intangibles) (USD) 17.4M 79M -131M -156M -137M -207M -234M
Income detail
Research and development expense (USD) 37.2M 62.1M 137M 164M 189M 240M 317M
↳ 5y CAGR +45.3% +38.5%
Total comprehensive income (USD) -41.2M -45.7M -101M -159M -143M -225M -308M
Comprehensive income to owners (USD) -41.2M -45.7M -101M -159M -143M -225M -308M
Reported Mar 11, 2021 Mar 11, 2021 Feb 24, 2022 Feb 22, 2024 Feb 22, 2024 Feb 27, 2025 Aug 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 29, 2026

PDF Version

KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile

KT-579 LUMORA Phase 1b trial in lupus patients planned to start by early 2027

Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial, with topline data to be reported by year-end 2026

KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be reported in late 2027

Well-capitalized with $1.6 billion in cash as of September 30, 2026, and runway into 2029

Company to hold video conference call and webcast today at 8:30 a.m. ET

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights and updates on its pipeline.

“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape. The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026. We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”

Dr. Mainolfi continued, “The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism. These findings exceed our expectations in terms of depth of degradation, safety and pathway suppression measured by downstream cytokines and gene transcripts. The results provide an important foundation as we advance KT-579, our 7th degrader to enter the clinic, toward a study in lupus patients and explore the opportunity for targeting IRF5 in additional autoimmune diseases. Beyond these clinical programs, our research engine remains focused on unlocking novel biology and pursuing high value targets to build the next wave of oral medicines for patients who need effective, safe and convenient treatment options.”

Business Highlights, Recent Developments and Upcoming Milestones

STAT6 Degrader Program KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in Phase 2 clinical development in atopic dermatitis (AD) and asthma. KT-621 has the potential to transform treatment paradigms by offering a safe, effective, oral option for the more than 140 million patients worldwide living with Type 2 diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.

  • In October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe AD. The Company plans to report topline data by year-end 2026. Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027.

  • Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027.

  • In September 2026, the Company presented data from the KT-621 BroADen Phase 1b clinical trial in AD across leading dermatology and respiratory forums, including posters at the European Academy of Dermatology and Venereology (EADV) and European Respiratory Society (ERS) Congresses.

IRF5 Degrader Program KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity. KT-579 has the potential to modulate multiple core inflammatory pathways through a single oral mechanism, offering a differentiated approach to serious autoimmune diseases where effective and well-tolerated oral therapies are needed, such as lupus, inflammatory bowel disease (IBD), Sjögren's, rheumatoid arthritis (RA) and others.

  • The Company today announced positive results from the completed first-in-human KT-579 Phase 1 healthy volunteer trial. The results met or exceeded study objectives and established strong proof of mechanism:

    • Pharmacokinetics and pharmacodynamics: KT-579 demonstrated a favorable plasma pharmacokinetic profile. Exposure increased with dose following single and multiple doses. Robust, sustained IRF5 degradation was observed following a single oral dose in the single ascending dose (SAD) portion of the trial. In the multiple ascending dose portion (MAD), KT-579 demonstrated deep, sustained IRF5 degradation in blood, with ≥90% median degradation across multiple dose levels with saturation of degradation by dose level 3. Similar reductions in IRF5 levels were also observed in skin, demonstrating target degradation in tissue as well as blood.
    • Ex vivo-stimulated IRF5-dependent biomarkers: KT-579 showed robust suppression of disease-relevant blood biomarkers and significant downregulation of pathway gene transcripts, reflecting pharmacodynamic effects on the three immune pathways modulated by IRF5 including inflammatory cytokines, interferon (IFN) response, and B-cell biology. The inflammatory cytokine and IFN analysis using the median of all MAD dose cohorts showed inhibition of 88% of TNFα, 87% of IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14. Gene-expression analyses also showed broad downregulation of inflammatory cytokine, interferon and B-cell associated genes, supporting the functional cytokine findings.
    • Safety and tolerability: The safety profile of KT-579 was comparable to placebo. There were no serious or severe adverse events (AEs) and no AEs leading to discontinuation. Very few mild treatment-related AEs were reported, and there was no dose-dependent pattern in treatment-emergent AEs. There were no clinically relevant changes in vital signs, laboratory tests or ECGs.
  • The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early 2027. LUMORA is a randomized, double-blind, placebo-controlled trial testing KT-579 in approximately 30 adult patients with systemic lupus erythematosus dosed over 16 weeks. The key aim of this biomarker study is to demonstrate that KT-579 can modulate underlying disease biology with a favorable safety and tolerability profile while exploring potential clinical benefits.

  • The Company will present new preclinical data on KT-579 in an oral presentation at the American College of Rheumatology (ACR) Convergence conference, taking place November 6-11, 2026, in Orlando, FL. The presentation will highlight KT-579’s compelling profile, including significant activity both as a monotherapy and in combination with background therapies in preclinical lupus models.

Partnered Programs & Research

  • The first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971) in healthy volunteers and hidradenitis suppurativa patients is ongoing. Under the collaboration, Sanofi is leading development, regulatory and commercial efforts for the program. KT-485 is a potent, selective, oral second-generation IRAK4 degrader with the potential to offer a novel approach for a range of chronic immuno-inflammatory diseases.

  • Gilead Sciences is advancing KT-200 in IND-enabling studies to support an IND filing in 2027. KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera and exclusively licensed to Gilead. KT-200 has the potential to improve the standard of care for patients with breast cancer and other solid tumors.

  • Leveraging its unique target selection strategy, proven small molecule discovery capabilities, and deep development expertise, the Company continues to advance an early pipeline of novel oral programs with a goal to deliver at least one new development candidate per year.

Corporate

  • In July 2026, the Company appointed Terence Rooney, MD, as Chief Medical Officer and Elizabeth Laws, PhD, as Senior Vice President, Global STAT6 Development Program Leader, strengthening its clinical development leadership to support the continued advancement of Kymera’s oral immunology portfolio.

Financial Results

Collaboration Revenues: There were no collaboration revenues for the third quarter of 2026 compared to $2.8 million for the third quarter of 2025. Collaboration revenues recognized in the third quarter of 2025 were all attributable to the Company’s collaboration with Gilead. The Company does not expect to recognize additional collaboration revenue in 2026.

Research and Development Expenses: Research and development expenses were $128.5 million for the third quarter of 2026 compared to $74.1 million for the third quarter of 2025. This increase was primarily due to increased expenses related to the investment in the Company’s STAT6 program, platform and discovery programs, as well as costs related to continued growth in the research and development organization. Stock based compensation expenses included in R&D were $10.9 million and $8.4 million for the third quarters of 2026 and 2025, respectively.

General and Administrative Expenses: General and administrative expenses were $18.7 million for the third quarter of 2026 compared to $17.3 million for the third quarter of 2025. The increase was primarily due to an increase in legal and professional service fees in support of the Company’s growth and an increase in personnel, facility, occupancy, and other expenses to support growth as a public company. Stock based compensation expenses included in G&A were $7.9 million and $7.4 million for the third quarters of 2026 and 2025, respectively.

**Net Loss:**Net loss was $132.0 million for the third quarter of 2026 compared to $82.2 million for the third quarter of 2025.

Cash and Cash Equivalents: As of September 30, 2026, Kymera had $1.6 billion in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash runway into 2029 beyond multiple clinical inflection points in its pipeline.

Event Details

Kymera will host a video conference call today, October 29, 2026, at 8:30 a.m. ET. To join the call please use this link to register. A live webcast of the event will be available under News and Events in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial condition and expected cash runway into 2029. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target,” “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that preclinical and clinical data, including the results from the Phase 1 trials of KT-621 and KT-579, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, and other factors. These risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

| KYMERA THERAPEUTICS, INC. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) |

| |

| | **September 30,**2026 | | **December 31,**2025 | |

| Assets | | | | |

| Cash, cash equivalents and marketable securities | $ | 1,645,883 | | $ | 1,619,434 | |

| Property and equipment, net | | 38,242 | | | 43,175 | |

| Right-of-use assets, operating lease | | 40,444 | | | 42,351 | |

| Other assets | | 42,700 | | | 37,852 | |

| Total assets | $ | 1,767,269 | | $ | 1,742,812 | |

| Liabilities and Stockholders’ Equity | | | | | | |

| Accrued expenses | $ | 63,315 | | $ | 42,274 | |

| Operating lease liabilities | | 74,626 | | | 78,975 | |

| Other liabilities | | 14,801 | | | 41,899 | |

| Total liabilities | | 152,742 | | | 163,148 | |

| Total stockholders’ equity | | 1,614,527 | | | 1,579,664 | |

| Total liabilities, preferred stock and stockholders’ equity | $ | 1,767,269 | | $ | 1,742,812 | |

| |

| KYMERA THERAPEUTICS, INC. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| Collaboration Revenue | $ | — | | | $ | 2,764 | | | $ | 99,365 | | | $ | 36,341 | | |

| | | | | | | | | | | | | | | | | |

| Operating expenses: | | | | | | | | | | | | | | | | |

| Research and development | $ | 128,509 | | | $ | 74,094 | | | $ | 346,152 | | | $ | 232,737 | | |

| General and administrative | | 18,723 | | | | 17,336 | | | | 60,207 | | | | 51,252 | | |

| Impairment of long-lived assets | | — | | | | 3,855 | | | | — | | | | 3,855 | | |

| Total operating expenses | | 147,232 | | | | 95,285 | | | | 406,359 | | | | 287,844 | | |

| Loss from operations | | (147,232 | ) | | | (92,521 | ) | | | (306,994 | ) | | | (251,503 | ) | |

| Other income (expense): | | | | | | | | | | | | | | | | |

| Interest and other income | | 15,295 | | | | 10,444 | | | | 44,753 | | | | 27,413 | | |

| Interest and other expense | | (62 | ) | | | (98 | ) | | | (203 | ) | | | (280 | ) | |

| Total other income | | 15,233 | | | | 10,346 | | | | 44,550 | | | | 27,133 | | |

| Net loss attributable to common stockholders | $ | (131,999 | ) | | $ | (82,175 | ) | | $ | (262,444 | ) | | $ | (224,370 | ) | |

| Net loss per share attributable to common stockholders, basic and diluted | $ | (1.32 | ) | | $ | (0.94 | ) | | $ | (2.66 | ) | | $ | (2.71 | ) | |

| Weighted average common stocks outstanding, basic and diluted | | 100,097,242 | | | | 87,300,286 | | | | 98,612,278 | | | | 82,653,142 | | |

| |

Investor Contact: Justine Koenigsberg [email protected] 857-285-5300

Media Contact: Matthew Henson [email protected] 857-285-5300

X CLOSE

October 28, 2026

PDF Version

WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event.

About KT-579 KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity. KT-579 has the potential to modulate multiple core inflammatory pathways through a single oral mechanism, offering a differentiated approach to serious autoimmune diseases where effective and well tolerated oral therapies are needed, such as lupus, Sjögren's, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and others.

About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: Justine Koenigsberg [email protected] 857-285-5300

Media Contact: Matthew Henson [email protected] 857-285-5300

X CLOSE

October 22, 2026

PDF Version

WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: Justine Koenigsberg [email protected] 857-285-5300

Media Contact: Matthew Henson [email protected] 857-285-5300

X CLOSE

Prompts

Kymera Therapeutics, Inc. (ticker KYMR), listed in United States.

ETFs Holding Kymera Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FMED 1.96% 8,500 $ 1.01M Aug 31, 2026
ARKG 0.85% 127,214 $ 15.459M Nov 18, 2026
MMSC 0.64% 2,538 $ 319.407K Nov 16, 2026
ILDR 0.61% 15,464 $ 1.946M Nov 16, 2026
TMED 0.47% 949 $ 108.822K Jun 30, 2026
ESSC 0.44% 1,522 $ 157.375K Jul 31, 2026
TMSL 0.43% 100,832 $ 11.562M Jun 30, 2026
FTKI 0.35% 703 $ 88.473K Nov 16, 2026
TGRT 0.31% 39,419 $ 4.961M Nov 17, 2026
FSEG 0.30% 148 $ 16.971K Jun 30, 2026
RUSC 0.26% 1,824 $ 209.158K Jun 30, 2026
RESM 0.26% 83 $ 9,517.61 Jun 30, 2026
TCAF 0.26% 219,870 $ 27.671M Nov 17, 2026
VFMO 0.20% 31,940 $ 3.795M Aug 31, 2026
FFSM 0.18% 25,352 $ 2.621M Jul 31, 2026
FFF 0.16% 93 $ 10.396K Sep 30, 2026
CLSE short -0.15% -11,041 $ -1.312M Aug 31, 2026
FESM 0.10% 50,241 $ 5.761M Jun 30, 2026
DFAS 0.10% 250,499 $ 31.856M Nov 12, 2026
IALT short -0.07% -41,719 $ -5.25M Nov 16, 2026
AVIE 0.06% 85 $ 10.697K Nov 16, 2026
AVMC 0.05% 2,373 $ 298.642K Nov 16, 2026
FBCG 0.05% 31,560 $ 3.263M Jul 31, 2026
MSSM 0.04% 2,614 $ 310.569K Aug 31, 2026
DFAC 0.02% 154,893 $ 19.698M Nov 12, 2026
AVLC 0.02% 2,082 $ 262.02K Nov 16, 2026
DFAU 0.01% 14,655 $ 1.864M Nov 12, 2026
DFSU 0.01% 2,447 $ 311.185K Nov 12, 2026
AVUS 0.01% 6,027 $ 758.498K Nov 16, 2026
DCOR 0.01% 32,992 $ 4.196M Nov 12, 2026
DFUS 0.00% 7,333 $ 932.538K Nov 12, 2026